Great post CJ! Now I'll just quote a little bit below, but every time I think of how important the KOL's were and the stage they are rising to is important leverage for Peregrine. I also think that these KOL's are rising fast in their already global circles because of their relations with Peregrine which is a bit ironic but hopefully we will hear lots more this month.
Peregrine Exhibiting & 3-Presentations Sept6-9 at IASLC World Conf. in Denver – recall, PPHM KOL/SAB’r Dr. David Carbone becomes President of The IASLC on 9-9-15. 3 Bavi presentations (1 poster, 1 Mini-Oral, 1 Oral) by UTSW (David Gerber, Rolf Brekken, Xianming Huang) and Moffitt CC (Scott Antonia), all with Peregrine co-authors…
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!